SCHEMBL4866567

SCHEMBL4866567

O=C(CCl)Nc1cccc2[nH]nnc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.46
HTT P42858 7/20 0.46
LMNA P02545 7/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
KDM4E B2RXH2 4/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
BLM P54132 2/20 0.41
NPSR1 Q6W5P4 1/20 0.39
NOD2 Q9HC29 1/20 0.39
PKM P14618 1/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
PAX8 Q06710 1/20 0.38
MITF O75030 2/20 0.36
XBP1 P17861 1/20 0.36
NPC1 O15118 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865097 0.83 POLB (0.40) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL29791629 0.83 MEN1 (0.41) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL31388185 0.80 ALDH1A1 (0.46) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL28435031 0.80 GAA (0.45) ALDH1A1KDM4EMAPTPOLB
SCHEMBL30776547 0.80 GAA (0.45) ALDH1A1KDM4EMAPTPOLB
SCHEMBL1757402 0.80 HTT (0.33) ALDH1A1HTTLMNASMN1; SMN2MEN1
SCHEMBL11669218 0.80 CETP (0.50) ALDH1A1LMNASMN1; SMN2KDM4EKMT2A
SCHEMBL29021933 0.80 NPC1 (0.40) ALDH1A1HTTKDM4EMEN1KMT2A
SCHEMBL31388206 0.79 ALDH1A1 (0.44) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL28458586 0.79 PLAU (0.38) ALDH1A1HTTLMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 245/4885HTT 2557/4885LMNA 2835/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885HTT 2259/4885LMNA 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.